Daniel Hetu

Kisoji Biotechnology, Inc. operates as a biotechnology company which develops cancer therapeutics through antibodies and stem cells. The company was founded by David S. Young and is headquartered in Montreal, Canada.

Lumira Capital Investment Management is a Venture Capital firm, a subsidiary of Nordion (Canada),Inc. founded in 1989 by Tony Pullen. The firm is headquartered in Toronto.

Lumira Capital Investment Management is a Venture Capital firm, a subsidiary of Nordion (Canada),Inc. founded in 1989 by Tony Pullen. The firm is headquartered in Toronto.

Gladius Pharmaceuticals, Inc. operates as a biotechnology company. It develops novel drugs to treat multi-drug-resistant bacterial infections. The company was founded by Larry D. Sutton and is headquartered in Montréal, Quebec.

Gladius Pharmaceuticals Corp. operates as a biotechnology firm. The company is headquartered in Wilmington, DE.

Gladius Pharmaceuticals, Inc. operates as a biotechnology company. It develops novel drugs to treat multi-drug-resistant bacterial infections. The company was founded by Larry D. Sutton and is headquartered in Montréal, Quebec.

Gladius Pharmaceuticals Corp. operates as a biotechnology firm. The company is headquartered in Wilmington, DE.

Specific Biologics, Inc. is a biotechnology company that focuses on developing gene editing technologies to treat diseases through precision gene editing. The company is based in Toronto, Canada. The Canadian company's two-site dualase™ platform gene editors cut DNA in a way that optimally exploits the cells naturally occurring DNA repair pathways, enabling two gene editing outcomes, precise DNA deletions to disrupt genes or increased repair to correct genes. Specific also develops lipid nanoparticles to deliver the gene editor to target cells and is developing a pipeline of dualase™-based therapeutics in areas of high unmet medical need. The company was founded in 2017. The CEO is Brent Stead.

Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA.

Lumira Capital Investment Management is a Venture Capital firm, a subsidiary of Nordion (Canada),Inc. founded in 1989 by Tony Pullen. The firm is headquartered in Toronto.

Transposon Therapeutics, Inc. provides pharmaceutical products. The company is headquartered in Westport, CT.

Transposon Therapeutics, Inc. provides pharmaceutical products. The company is headquartered in Westport, CT.

Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA.

Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA.

Lumira Capital Investment Management is a Venture Capital firm, a subsidiary of Nordion (Canada),Inc. founded in 1989 by Tony Pullen. The firm is headquartered in Toronto.

Specific Biologics, Inc. is a biotechnology company that focuses on developing gene editing technologies to treat diseases through precision gene editing. The company is based in Toronto, Canada. The Canadian company's two-site dualase™ platform gene editors cut DNA in a way that optimally exploits the cells naturally occurring DNA repair pathways, enabling two gene editing outcomes, precise DNA deletions to disrupt genes or increased repair to correct genes. Specific also develops lipid nanoparticles to deliver the gene editor to target cells and is developing a pipeline of dualase™-based therapeutics in areas of high unmet medical need. The company was founded in 2017. The CEO is Brent Stead.

Lumira Capital Investment Management is a Venture Capital firm, a subsidiary of Nordion (Canada),Inc. founded in 1989 by Tony Pullen. The firm is headquartered in Toronto.

Lumira Capital Investment Management is a Venture Capital firm, a subsidiary of Nordion (Canada),Inc. founded in 1989 by Tony Pullen. The firm is headquartered in Toronto.

Gladius Pharmaceuticals, Inc. operates as a biotechnology company. It develops novel drugs to treat multi-drug-resistant bacterial infections. The company was founded by Larry D. Sutton and is headquartered in Montréal, Quebec.

Specific Biologics, Inc. is a biotechnology company that focuses on developing gene editing technologies to treat diseases through precision gene editing. The company is based in Toronto, Canada. The Canadian company's two-site dualase™ platform gene editors cut DNA in a way that optimally exploits the cells naturally occurring DNA repair pathways, enabling two gene editing outcomes, precise DNA deletions to disrupt genes or increased repair to correct genes. Specific also develops lipid nanoparticles to deliver the gene editor to target cells and is developing a pipeline of dualase™-based therapeutics in areas of high unmet medical need. The company was founded in 2017. The CEO is Brent Stead.

Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA.

Kisoji Biotechnology, Inc. operates as a biotechnology company which develops cancer therapeutics through antibodies and stem cells. The company was founded by David S. Young and is headquartered in Montreal, Canada.

Lumira Capital Investment Management is a Venture Capital firm, a subsidiary of Nordion (Canada),Inc. founded in 1989 by Tony Pullen. The firm is headquartered in Toronto.

Lumira Capital Investment Management is a Venture Capital firm, a subsidiary of Nordion (Canada),Inc. founded in 1989 by Tony Pullen. The firm is headquartered in Toronto.

Lumira Capital Investment Management is a Venture Capital firm, a subsidiary of Nordion (Canada),Inc. founded in 1989 by Tony Pullen. The firm is headquartered in Toronto.

Specific Biologics, Inc. is a biotechnology company that focuses on developing gene editing technologies to treat diseases through precision gene editing. The company is based in Toronto, Canada. The Canadian company's two-site dualase™ platform gene editors cut DNA in a way that optimally exploits the cells naturally occurring DNA repair pathways, enabling two gene editing outcomes, precise DNA deletions to disrupt genes or increased repair to correct genes. Specific also develops lipid nanoparticles to deliver the gene editor to target cells and is developing a pipeline of dualase™-based therapeutics in areas of high unmet medical need. The company was founded in 2017. The CEO is Brent Stead.

Lumira Capital Investment Management is a Venture Capital firm, a subsidiary of Nordion (Canada),Inc. founded in 1989 by Tony Pullen. The firm is headquartered in Toronto.

Transposon Therapeutics, Inc. provides pharmaceutical products. The company is headquartered in Westport, CT.

Gladius Pharmaceuticals Corp. operates as a biotechnology firm. The company is headquartered in Wilmington, DE.

Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA.

Gladius Pharmaceuticals, Inc. operates as a biotechnology company. It develops novel drugs to treat multi-drug-resistant bacterial infections. The company was founded by Larry D. Sutton and is headquartered in Montréal, Quebec.

Lumira Capital Investment Management is a Venture Capital firm, a subsidiary of Nordion (Canada),Inc. founded in 1989 by Tony Pullen. The firm is headquartered in Toronto.

Specific Biologics, Inc. is a biotechnology company that focuses on developing gene editing technologies to treat diseases through precision gene editing. The company is based in Toronto, Canada. The Canadian company's two-site dualase™ platform gene editors cut DNA in a way that optimally exploits the cells naturally occurring DNA repair pathways, enabling two gene editing outcomes, precise DNA deletions to disrupt genes or increased repair to correct genes. Specific also develops lipid nanoparticles to deliver the gene editor to target cells and is developing a pipeline of dualase™-based therapeutics in areas of high unmet medical need. The company was founded in 2017. The CEO is Brent Stead.

Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA.

Transposon Therapeutics, Inc. provides pharmaceutical products. The company is headquartered in Westport, CT.

Transposon Therapeutics, Inc. provides pharmaceutical products. The company is headquartered in Westport, CT.

Transposon Therapeutics, Inc. provides pharmaceutical products. The company is headquartered in Westport, CT.

Lumira Capital Investment Management is a Venture Capital firm, a subsidiary of Nordion (Canada),Inc. founded in 1989 by Tony Pullen. The firm is headquartered in Toronto.

Congruence Therapeutics, Inc. operates as a Canadian biotechnology company. The company is based in Westmount, Canada. Congruence Therapeutics was founded in 2021 by Clarissa Desjardins, who has been the CEO since 2021.

Kisoji Biotechnology, Inc. operates as a biotechnology company which develops cancer therapeutics through antibodies and stem cells. The company was founded by David S. Young and is headquartered in Montreal, Canada.

Lumira Capital Investment Management is a Venture Capital firm, a subsidiary of Nordion (Canada),Inc. founded in 1989 by Tony Pullen. The firm is headquartered in Toronto.

Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA.

Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA.

Kisoji Biotechnology, Inc. operates as a biotechnology company which develops cancer therapeutics through antibodies and stem cells. The company was founded by David S. Young and is headquartered in Montreal, Canada.

Lumira Capital Investment Management is a Venture Capital firm, a subsidiary of Nordion (Canada),Inc. founded in 1989 by Tony Pullen. The firm is headquartered in Toronto.

Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA.

Xylocor Therapeutics, Inc. engages in the biopharmaceutical company that develops gene therapy for people with advanced coronary artery disease. It focuses on developing product for patients with refractory angina with no treatment options and its secondary product for patients with cardiac tissue damage from heart attacks. The company was founded by Ronald Crystal and Todd Rosengart in 2013 and is headquartered in Malvern, PA.

Transposon Therapeutics, Inc. provides pharmaceutical products. The company is headquartered in Westport, CT.

Congruence Therapeutics, Inc. operates as a Canadian biotechnology company. The company is based in Westmount, Canada. Congruence Therapeutics was founded in 2021 by Clarissa Desjardins, who has been the CEO since 2021.

Specific Biologics, Inc. is a biotechnology company that focuses on developing gene editing technologies to treat diseases through precision gene editing. The company is based in Toronto, Canada. The Canadian company's two-site dualase™ platform gene editors cut DNA in a way that optimally exploits the cells naturally occurring DNA repair pathways, enabling two gene editing outcomes, precise DNA deletions to disrupt genes or increased repair to correct genes. Specific also develops lipid nanoparticles to deliver the gene editor to target cells and is developing a pipeline of dualase™-based therapeutics in areas of high unmet medical need. The company was founded in 2017. The CEO is Brent Stead.